Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish between patients with FTLD-TDP and FTLD-tau. Therefore, we evaluated truncated stathmin-2 (STMN2) as a proxy of TDP-43 pathology, given the reports that TDP-43 dysfunction causes truncated STMN2 accumulation. Truncated STMN2 accumulated in human induced pluripotent stem cell-derived neurons depleted of TDP-43, but not in those with pathogenic TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein. In RNA-Seq analyses of human brain samples from the NYGC ALS cohort, truncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP-43 inclusions. Last, we validated that truncated STMN2 RNA was elevated in the frontal cortex of a cohort of patients with FTLD-TDP but not in controls or patients with progressive supranuclear palsy, a type of FTLD-tau. Further, in patients with FTLD-TDP, we observed significant associations of truncated STMN2 RNA with phosphorylated TDP-43 levels and an earlier age of disease onset. Overall, our data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 1×
“36) (54), all samples were aligned to the hg38 build (GRCh38.”
BackgroundThe Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · cited 2×
“Age at death (yr) 82 (55, 99) 69 (52, 86) 72 (49, 100) 76 (50, 100) 67 (49, 98) 74 (60, 84) 63 (61, 64)”
Methodfastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721 · cited 1×
“fastp (47) and aligned to the hg38 build (GRCh38.”
BackgroundfeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 2×
“Age at death (yr) 82 (55, 99) 69 (52, 86) 72 (49, 100) 76 (50, 100) 67 (49, 98) 74 (60, 84) 63 (61, 64)”
MethodRSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
MultiQC: summarize analysis results for multiple tools and samples in a single report
Ewels, P., Magnusson, M., Lundin, S., & Käller, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw354 · Cited by 10,143 · cited 2×
“Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report.”
MethodUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“Cells with TDP-43 pathology feature a redistribution of TDP-43 from the nucleus to the cytoplasm, where TDP-43 is ubiquitinated, hyperphosphorylated, and cleaved into C-terminal fragments (14).”
BackgroundThe GTEx Consortium atlas of genetic regulatory effects across human tissues
The GTEx Consortium, Aguet, F., Anand, S., Ardlie, K. G., Gabriel, S., Getz, G. A., Graubert, A., Hadley, K., Handsaker, R. E., Huang, K. H., et al. (2020) · Science · doi:10.1126/science.aaz1776 · Cited by 5,547 · cited 3×
“the criteria of the Genotype Tissue Expression Consortium (64).”
BackgroundSelf-citation
Cited by
TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A
Ma, X. R., Prudencio, M., Koike, Y., Vatsavayai, S. C., Kim, G., Harbinski, F., Briner, A., Rodriguez, C. M., Guo, C., Akiyama, T., et al. (2022) · Nature · doi:10.1038/s41586-022-04424-7 · Cited by 574
“This work was supported by NIH grants R35NS097263(10) (A.”
BackgroundSelf-citationTDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A
Brown, A.-L., Wilkins, O. G., Keuss, M. J., Kargbo-Hill, S. E., Zanovello, M., Lee, W. C., Bampton, A., Lee, F. C. Y., Masino, L., Qi, Y. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04436-3 · Cited by 529
“Our approach, based on our previous work (Prudencio, 2020), has the advantage of assessing TDP-43 pathology and UNC13A mis-splicing within the same sample.”
Self-citationMead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation
Tziortzouda, P., Van Den Bosch, L., & Hirth, F. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00431-1 · Cited by 267
Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies
Baughn, M. W., Melamed, Z., López-Erauskin, J., Beccari, M. S., Ling, K., Zuberi, A., Presa, M., Gonzalo-Gil, E., Maimon, R., Vazquez-Sanchez, S., et al. (2023) · Science · doi:10.1126/science.abq5622 · Cited by 239
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Self-citationMis-spliced transcripts generate de novo proteins in TDP-43–related ALS/FTD
Seddighi, S., Qi, Y. A., Brown, A.-L., Wilkins, O. G., Bereda, C., Belair, C., Zhang, Y.-J., Prudencio, M., Keuss, M. J., Khandeshi, A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7162 · Cited by 188
“One such example is the well-characterized CE in stathmin-2 ( STMN2 ), which causes loss of STMN2 mRNA and protein in the cortex and spinal cord of patients with ALS or with frontotemporal lobar degeneration (FTLD; a subset of FTD) ( 12 – 14 ).”
BackgroundSelf-citationA fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD
Irwin, K. E., Jasin, P., Braunstein, K. E., Sinha, I. R., Garret, M. A., Bowden, K. D., Chang, K., Troncoso, J. C., Moghekar, A., Oh, E. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02788-5 · Cited by 163
“9,11–14,25–27).”
The era of cryptic exons: implications for ALS-FTD
Mehta, P. R., Brown, A.-L., Ward, M. E., & Fratta, P. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00608-5 · Cited by 146
“This proof of concept was first shown with the STMN2 cryptic exon in post-mortem frontal cortex samples, in which its presence was able to discriminate between patients with FTD-TDP, progressive supranuclear palsy, and healthy control participants [31].”
BackgroundSelf-citationCoyne, A. N., Baskerville, V., Zaepfel, B. L., Dickson, D. W., Rigo, F., Bennett, F., Lusk, C. P., & Rothstein, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe1923 · Cited by 143
Self-citationHumphrey, J., Venkatesh, S., Hasan, R., Herb, J. T., de Paiva Lopes, K., Küçükali, F., Byrska-Bishop, M., Evani, U. S., Narzisi, G., Fagegaltier, D., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01205-3 · Cited by 138
Self-citationLoss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy
Krus, K. L., Strickland, A. M., Yamada, Y., DeVault, L., Schmidt, R. E., Bloom, A. J., Milbrandt, J., & DiAntonio, A. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111001 · Cited by 129
Antisense Oligonucleotides for the Study and Treatment of ALS
Boros, B. D., Schoch, K. M., Kreple, C. J., & Miller, T. M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01247-2 · Cited by 121
Molecular subtypes of ALS are associated with differences in patient prognosis
Eshima, J., O’Connor, S. A., Marschall, E., NYGC ALS Consortium, Bowser, R., Plaisier, C. L., & Smith, B. S. (2023) · Nature Communications · doi:10.1038/s41467-022-35494-w · Cited by 79
“Both the Prudencio et al.(10) and Tam et al.”
BackgroundMethodInfluentialLoss of mouse Stmn2 function causes motor neuropathy
Juan, I. G. S., Nash, L. A., Smith, K. S., Leyton-Jaimes, M. F., Qian, M., Klim, J. R., Limone, F., Dorr, A. B., Couto, A., Pintacuda, G., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.02.011 · Cited by 92
Quadros, A. R. A. D. A., Li, Z., Wang, X., Ndayambaje, I. S., Aryal, S., Ramesh, N., Nolan, M., Jayakumar, R., Han, Y., Stillman, H., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02655-0 · Cited by 81
“Mis-processing of STMN2 is detected in post-mortem tissues of patients with sporadic and familial forms of ALS and FTD [42, 62, 76].”
Self-citationConnecting TDP-43 Pathology with Neuropathy
Klim, J. R., Pintacuda, G., Nash, L. A., Juan, I. G. S., & Eggan, K. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.02.008 · Cited by 76
Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology
Ziff, O. J., Neeves, J., Mitchell, J. S., Tyzack, G. E., Martínez‐Ruiz, C., Luisier, R., Chakrabarti, A. M., McGranahan, N., Litchfield, K., Boulton, S. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37630-6 · Cited by 86
Self-citationSanchez, I., Nguyen, T. B., England, W., Lim, R. G., Vu, A. Q., Miramontes, R., Byrne, L. M., Markmiller, S., Lau, A., Orellana, I., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140723 · Cited by 68
“Hirsch-Reinshagen V, et al. Clinical and neuropathological features of ALS/FTD with TIA1 mutations.”
BackgroundInfluentialTDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains
Ayuso, V. E., Pickles, S. R., Todd, T. W., Yue, M., Jansen‐West, K. R., Song, Y., Bejarano, J. G., Rawlinson, B. D., Deture, M. A., Graff‐Radford, N. R., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00646-z · Cited by 78
“The accumulation of cryptic STMN2 RNA in ALS/ FTLD-TDP is accompanied by a decrease in full-length STMN2 RNA and protein [31, 32, 35].”
BackgroundMethodInfluentialSelf-citationCell environment shapes TDP-43 function with implications in neuronal and muscle disease
Šušnjar, U., Škrabar, N., Brown, A., Abbassi, Y., Phatnani, H. P., Phatnani, H. P., Fratta, P., Kwan, J. Y., Sareen, D., Broach, J. R., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03253-8 · Cited by 60
Self-citationLópez‐Erauskin, J., Bravo‐Hernández, M., Presa, M. F., Baughn, M. W., Melamed, Z., Beccari, M. S., Quadros, A. R. A. D. A., Arnold-García, O., Zuberi, A. R., Ling, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01496-0 · Cited by 62
“TDP-43 suppression in human cells drives the use of cryptic splice and polyadenylation sites in the STMN2 pre-mRNA, producing a truncated, nonfunctional mRNA that includes a new exon 2a that accumulates in brain and spinal cord of patients with TDP-43 pathology 33–35 .”
Gittings, L. M., Alsop, E. B., Antone, J., Singer, M., Whitsett, T. G., Sattler, R., & Keuren‐Jensen, K. R. V. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02599-5 · Cited by 64
“A recently described phenotype governed by the mislocalization of TDP-43 in ALS-TDP and FTD-TDP is a failure of TDP-43 to repress the inclusion of cryptic exons (CEs) in several RNA transcript targets of TDP-43 [4, 23, 24, 29, 33, 39, 50].”
BackgroundInfluentialChang, K., Ling, J. P., Redding‐Ochoa, J., An, Y., Li, L., Dean, S. A., Blanchard, T. G., Pylyukh, T., Barrett, A., Irwin, K. E., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02653-2 · Cited by 61
“An important function of TDP-43 is repressing the splicing of cryptic exons [13, 46, 50, 52, 57, 75].”
Bampton, A., Gatt, A. P., Humphrey, J., Cappelli, S., Bhattacharya, D., Foti, S. C., Brown, A., Asi, Y. T., Low, Y. H., Foiani, M., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02340-0 · Cited by 56
“Cryptic exon inclusion can trigger premature polyadenylation leading to a sharp decline in protein expression, as in the case of STMN2/stathmin-2 [34, 48, 57].”
BackgroundSelf-citationSpence, H., Waldron, F. M., Saleeb, R. S., Brown, A., Rifai, O. M., Gilodi, M., Read, F. L., Roberts, K., Milne, G., Wilkinson, D., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02705-1 · Cited by 57
“[20] found truncated STMN-2 to be a highly specific biomarker for FTLD-TDP, as STMN-2 was absent in brain tissues of patients with FTLD-FUS, FTLD-tau and in controls, and was absent in spinal cords of patients with ALS-SOD1 and in controls.”
BackgroundResultInfluentialSelf-citationNguyen, T. B., Miramontes, R., Chillón-Marinas, C., Maimon, R., Vazquez‐Sanchez, S., Lau, A., McClure, N. R., Wu, Z., Wang, K. Q., England, W., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-024-01850-w · Cited by 72
“TDP-43 acts as a repressor of CEs in ALS/FTD, with TDP-43 nuclear loss resulting in increased inclusion of CEs 33–36, 74 , 75 .”
Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy
Balendra, R., Sreedharan, J., Hallegger, M., Luisier, R., Lashuel, H. A., Gregory, J. M., & Patani, R. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00109-7 · Cited by 66
“The second study used a non-biased screening approach in CSF from people with ALS or frontotemporal dementia and found 18 de novo cryptic peptides across 13 genes.”
An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients
Phatnani, H. P., Kwan, J. Y., Sareen, D., Broach, J. R., Simmons, Z., Arcila-Londono, X., Lee, E. B., Deerlin, V. M. V., Shneider, N. A., Fraenkel, E., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103221 · Cited by 58
Self-citationGranulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology
de Majo, M., Koontz, M., Marsan, E., Salinas, N., Ramsey, A., Kuo, Y.-M., Seo, K., Li, H., Dräger, N., Leng, K., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.01.012 · Cited by 44
Self-citationTheunissen, F., West, P. K., Brennan, S. E., Petrović, B., Hooshmand, K., Akkari, P. A., Keon, M., & Guennewig, B. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00272-z · Cited by 50
“Abbreviations ATP: Adenosine triphosphate; TUBA4A: Alpha-tubulin 4a; AD: Alzheimer’s disease; ALS: Amyotrophic lateral sclerosis; CNS: Central nervous system; CMT: Charcot-Marie-Tooth disease; cGAS: Cyclic guanosine monophosphate-adenosine monophosphate synthase; DRP1: Dynamin-related protein-1; DYNC1H1 and DYNC1H2: D…”
BackgroundInfluentialNovel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype
Theunissen, F., Anderton, R. S., Mastaglia, F. L., Flynn, L. L., Winter, S. J., JAMES, I. R., Bedlack, R., Hodgetts, S. I., Fletcher, S., Wilton, S. D., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.658226 · Cited by 49
TDP-43 Proteinopathy Specific Biomarker Development
Cordts, I., Wachinger, A., Scialò, C., Lingor, P., Polymenidou, M., Buratti, E., & Feneberg, E. (2023) · Cells · doi:10.3390/cells12040597 · Cited by 55
“Truncated and non-functional STMN2 mRNA, caused by premature polyadenylation resulting in an eightfold reduction of normal STMN2 levels, was found in the TDP-43 proteinopathy positive postmortem brain regions of FTD patients [82].”
BackgroundMarks, J. D., Ayuso, V. E., Carlomagno, Y., Yue, M., Todd, T. W., Hao, Y., Li, Z., McEachin, Z. T., Shantaraman, A., Duong, D. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adf9735 · Cited by 47
“Loss of TDP-43 function has been shown to lead to the aberrant incorporation of a premature stop codon in STMN2 ( 16 , 29 , 30 ), and we recently demonstrated that the abnormal production of truncated STMN2 ( tSTMN2 ) transcripts provides a sensitive readout of TDP-43 dysfunction, accurately…”
BackgroundMethodSelf-citationRothstein, J. D., Baskerville, V., Rapuri, S., Mehlhop, E., Jafar‐Nejad, P., Rigo, F., Bennett, F., Mizielinska, S., Isaacs, A. M., & Coyne, A. N. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02652-3 · Cited by 48
“…TDP-43 is only observed in a small percentage of CNS cells in C9orf72 patients at autopsy [8, 25, 36], suggesting that more histologically subtle nuclear depletion may be sufficient to induce robust alterations in TDP-43 function as has been demonstrated for STMN2 in patient CNS tissues [32, 37].”
BackgroundCreation of de novo cryptic splicing for ALS and FTD precision medicine
Wilkins, O. G., Chien, M. Z. Y. J., Wlaschin, J. J., Barattucci, S., Harley, P., Mattedi, F., Mehta, P. R., Pisliakova, M., Ryadnov, E. M., Keuss, M. J., et al. (2024) · Science · doi:10.1126/science.adk2539 · Cited by 51
“Transformation of DNA was performed with Stbl3 bacteria (ThermoFisher Scientific); for the transformation of Gibson assembly products, the reaction mixtures were first purified using SPRI beads to avoid toxicity (Mag-bind TotalPure NGS; Omega-Bio-tek).”
Self-citationGil, R. S., Pascovici, D., Venturato, J., Brown-Wright, H., Mehta, P. M., Martin, L. M. S., Wu, J. X., Luan, W., Chui, Y. K., Bademosi, A. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45646-9 · Cited by 40
Stress-induced TDP-43 nuclear condensation causes splicing loss of function and STMN2 depletion
Huang, W.-P., Ellis, B. C. S., Hodgson, R. E., Avila, A. S., Kumar, V., Rayment, J. A., Moll, T., & Shelkovnikova, T. A. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114421 · Cited by 48
TDP-43 in nuclear condensates: where, how, and why
Lang, R., Hodgson, R. E., & Shelkovnikova, T. A. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231447 · Cited by 40
TDP-43 loss induces cryptic polyadenylation in ALS/FTD
Bryce-Smith, S., Brown, A., Chien, M. Z. Y. J., Dattilo, D., Mehta, P. R., Mattedi, F., Barattucci, S., Mikheenko, A., Zanovello, M., Pellegrini, F., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02050-w · Cited by 74
“Previous work identified cryptic ALEs, as their novel splice junction can be detected by numerous splice detection packages 13,35,57 .”
Self-citationTDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes
Zeng, Y., Lovchykova, A., Akiyama, T., Rayner, S. L., Jawahar, V. M., Liu, C., Sianto, O., Guo, C., Calliari, A., Prudencio, M., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02049-3 · Cited by 82
“RNA was extracted from the frontal cortices of healthy and FTD patients following the manufacturer’s protocol using the RNAeasy Plus Mini Kit (Qiagen) and as previously described 9,11,63 .”
Self-citationA fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALSPreprint
Irwin, K. E., Jasin, P., Braunstein, K., Sinha, I. R., Bowden, K. D., Moghekar, A., Oh, E. S., Raitcheva, D., Bartlett, D., Berry, J., et al. (2023) · bioRxiv · doi:10.1101/2023.01.23.525202 · Cited by 40
“…so while such TDP-43 functional deficits are well-documented in end-stage tissues (Brown et al., 2022; Klim et al., 2019; Ma et al., 2022; Melamed et al., 2019; Prudencio et al., 2020), the extent to which loss of TDP-43 splicing repression occurs during the early stages of disease is unclear.”
BackgroundStathmins and Motor Neuron Diseases: Pathophysiology and Therapeutic Targets
Gagliardi, D., Pagliari, E., Meneri, M., Melzi, V., Rizzo, F., Comi, G. P., Corti, S. P., Taiana, M. M., & Nizzardo, M. (2022) · Biomedicines · doi:10.3390/biomedicines10030711 · Cited by 37
“Moreover, reduced STMN2 expression was more recently reported in the brains of patients with Parkinson’s disease [44] and frontotemporal dementia [42] and in patients without TDP-43 pathology and in the absence of truncated STMN2, suggesting that STMN2 expression could be regulated by other mechanisms that are differe…”
BackgroundSattler, R., Traynor, B. J., Robertson, J., Bosch, L. V. D., Barmada, S. J., Svendsen, C. N., Disney, M. D., Gendron, T. F., Wong, P. C., Turner, M. R., et al. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00548-8 · Cited by 34
Self-citationTDP-43 proteinopathy in ALS is triggered by loss of ASRGL1 and associated with HML-2 expression
Montojo, M. G., Fathi, S., Rastegar, C. T., Simula, E. R., Doucet-O’Hare, T. T., Cheng, Y.-H. H., Abrams, R. P. M., Pasternack, N., Malik, N., Bachani, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48488-7 · Cited by 35
“Truncated forms of STMN2 are elevated in the brain of patients with FTD and is a marker for TDP-43 dysfunction 66 .”
BackgroundCryptic exon inclusion is a molecular signature of LATE-NC in aging brains
Chung, M., Carter, E. K., Veire, A. M., Dammer, E. B., Chang, J., Duong, D. M., Raj, N., Bassell, G. J., Glass, J. D., Gendron, T. F., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02671-0 · Cited by 35
“…cryptic exon splicing events in human post-mortem brain has been investigated in ALS, FTLD-TDP, and more recently, AD [6, 13, 23, 25, 27, 43, 49]; however, studies investigating whether neuronally enriched cryptic exons accumulate in the most common TDP-43 proteinopathy, LATE-NC, are…”
BackgroundSelf-citationEmerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder
Marchi, F. D., Franjkic, T., Schito, P., Russo, T., Nimac, J., Chami, A. A., Mele, A., Vidatic, L., Križ, J., Julien, J., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061599 · Cited by 31
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases
Calliari, A., Daughrity, L. M., Albagli, E. A., Otero, P. C., Yue, M., Jansen‐West, K. R., Islam, N. N., Caulfield, T. R., Rawlinson, B. D., Deture, M. A., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00718-8 · Cited by 36
Self-citationDuong, M. T., & Wolk, D. A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01232-4 · Cited by 33
Imaizumi, K., Ideno, H., Sato, T., Morimoto, S., & Okano, H. (2022) · eNeuro · doi:10.1523/eneuro.0061-22.2022 · Cited by 32
Reviewing the Potential Links between Viral Infections and TDP-43 Proteinopathies
Rahic, Z., Buratti, E., & Cappelli, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021581 · Cited by 30
“Very recently, this has been clearly observed in patients by the detection of “cryptic” exons inclusion in important genes, such as UNC13A and STMN2, where the absence of TDP-43 during the splicing process induces the spliceosome to include pre-mRNA sequences in the mature mRNA which in normal conditions would never h…”
BackgroundRecent Advances in Extracellular Vesicles in Amyotrophic Lateral Sclerosis and Emergent Perspectives
Afonso, G. J. M., Cavaleiro, C., Valero, J., Mota, S. I., & Ferreiro, E. B. (2023) · Cells · doi:10.3390/cells12131763 · Cited by 29
“An important player in the pathophysiology of ALS patients carrying C9ORF72 expansion is poly GA, which induces the intracellular aggregation of phosphorylated TDP-43 proteins through the impairment of TDP43 nuclear translocation and cytoplasmic mislocation [66,67].”
BackgroundTargeting common disease pathomechanisms to treat amyotrophic lateral sclerosis
Faller, K. M. E., Chaytow, H., & Gillingwater, T. H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-024-01049-4 · Cited by 34
“Conversely, given that the presence of the STMN2 cryptic exon seems to be specific to TDP-43 pathology, it has potential for use as a biomarker both for distinguishing TDP-43 proteinopathies 33 and even as an indirect assessment of efficacy for TDP-43-targeting therapies 34 .”
Kempthorne, L., Vaizoglu, D., Cammack, A. J., Carcolé, M., Roberts, M. J., Mikheenko, A., Fisher, A., Suklai, P., Muralidharan, B., Kroll, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55550-x · Cited by 27
“…or antisense knockdown could prevent glutamate-induced excitotoxicity, a well-studied phenotype associated with C9orf72 expression in iPSC-neurons 37 – 40 , and expression of cryptic exons previously observed in ALS 41 – 45 , which have been previously shown in these lines by this timepoint 20 .”
Self-citationPathogenic Genome Signatures That Damage Motor Neurons in Amyotrophic Lateral Sclerosis
Yousefian-Jazi, A., Seol, Y., Kim, J., Ryu, H. L., Lee, J.-H., & Ryu, H. (2020) · Cells · doi:10.3390/cells9122687 · Cited by 35
“of nuclear TDP-43 inhibits regeneration of motor axons, which is the consequence of reduction in stathmin-2 (STMN2), an essential protein for axonal growth and maintenance (Figure 3B) [117,118].”
BackgroundAkiyama, T., Koike, Y. M., Petrucelli, L., & Gitler, A. D. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.818 · Cited by 27
Self-citationThe Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer’s Disease
Bendtsen, K. M., & Hall, V. J. (2023) · Cells · doi:10.3390/cells12030420 · Cited by 33
TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS/FTD
Joseph, B. J., Marshall, K. A., Harley, P., Mann, J. R., Alessandrini, F., Vanoye, C. G., Chi, W., Prudencio, M., Simkin, D., Kao, T.-T., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02096-w · Cited by 41
“The recent interrogation of human induced pluripotent stem cell (iPS cell)-derived neurons with loss of TDP-43 function and postmortem tissue from patients with ALS has revealed hundreds of target mRNAs that undergo mis-splicing 9–13 .”
Self-citationThornburg‐Suresh, E. J. C., Richardson, J. E., & Summers, D. W. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104861 · Cited by 34
Biomarkers in frontotemporal dementia: Current landscape and future directions
Gifford, A., Praschan, N. C., Newhouse, A. L., & Chemali, Z. N. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100065 · Cited by 33
Advances in sequencing technologies for amyotrophic lateral sclerosis research
Udine, E., Jain, A., & van Blitterswijk, M. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00593-1 · Cited by 45
TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changesPreprint
Zeng, Y., Lovchykova, A., Akiyama, T., Liu, C., Guo, C., Jawahar, V. M., Sianto, O., Calliari, A., Prudencio, M., Dickson, D. W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.22.575730 · Cited by 25
Self-citationEvidence of cerebellar TDP-43 loss of function in FTLD-TDP
Pickles, S. R., Gendron, T. F., Koike, Y. M., Yue, M., Song, Y., Kachergus, J. M., Shi, J., Deture, M. A., Thompson, E. A., Oskarsson, B., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01408-6 · Cited by 25
“We recently demonstrated that a truncated variant of STMN2 (tSTMN2), generated by the aberrant inclusion of a stop-codon containing cryptic exon, is detected in the central nervous system of ALS and FTLD cases with TDP-43 proteinopathy [28].”
BackgroundMethodResultSelf-citationUpdates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis
Nguyen, L. (2024) · Cells · doi:10.3390/cells13110888 · Cited by 34
TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTDPreprint
Bryce-Smith, S., Brown, A., Mehta, P. R., Mattedi, F., Mikheenko, A., Barattucci, S., Zanovello, M., Dattilo, D., Yome, M., Kargbo-Hill, S. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.22.576625 · Cited by 24
“Cryptic ALEs (n=92) included previously identified cryptic exons such as STMN2 , ARHGAP32, and RSF1 ( Fig.”
InfluentialSelf-citationElevated nuclear TDP-43 induces constitutive exon skipping
Carmen-Orozco, R. P., Tsao, W., Ye, Y., Sinha, I. R., Chang, K., Trinh, V. T., Chung, W., Bowden, K., Troncoso, J. C., Blackshaw, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00732-w · Cited by 27
Yu, Q.-S., Feng, W.-Q., Shi, L., Niu, R., & Liu, J. (2022) · Brain Sciences · doi:10.3390/brainsci12081022 · Cited by 24
Cao, M. C., Ryan, B., Wu, J., Curtis, M. A., Faull, R. L. M., Dragunow, M., & Scotter, E. L. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106245 · Cited by 23
“Diagnostic approaches to testing DEU changes or cryptic exon emergence include PCR or RNAsequencing of biofluids at the transcriptome level (Koh et al., 2014; Prudencio et al., 2020), or aptamers or antibodies to assay cryptic peptides or neoepitopes at the protein level (Seddighi et al.”
Progranulin deficiency in the brain: the interplay between neuronal and non-neuronal cells
Gawęda-Walerych, K., Aragona, V., Lodato, S., Sitek, E. J., Narożańska, E., & Buratti, E. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00475-8 · Cited by 23
“Accordingly, mis-splicing of STMN2 transcripts has recently become an established marker of TDP-43 pathology and is correlated with the level of phospho-TDP-43 pathology in the brains of patients [122, 190, 191].”
Genetic architecture of motor neuron diseases
Chaudhary, R., Agarwal, V., Rehman, M., Kaushik, A. S., & Mishra, V. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120099 · Cited by 27
Cao, M. C., & Scotter, E. L. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049418 · Cited by 26
“Loss of STMN2 expression following TDP-43 depletion is associated with the emergence of a cryptic exon after exon 1, which introduces a premature polyadenylation site (Prudencio et al., 2020).”
Smith, A. S. T., Chun, C., Hesson, J., Mathieu, J., Valdmanis, P. N., Mack, D. L., Choi, B., Kim, D., & Bothwell, M. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.728707 · Cited by 25
Self-citationKe, Y. D., van Hummel, A., Au, C. G., Chan, G., Lee, W. S., van der Hoven, J., Przybyla, M., Deng, Y., Sabale, M., Morey, N., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.022 · Cited by 24
Rothstein, J. D., Keeley, O., Warlick, C., Miller, T. M., Ly, C. V., Glass, J. D., & Coyne, A. N. (2025) · Nature Communications · doi:10.1038/s41467-025-62482-7 · Cited by 30
“Nonetheless,this variability holds implications for future sALS focused clinical trials either targeting individual mRNA targets of TDP-43 20,24,28,29 or those seeking to utilize TDP-43 loss of functionassociated “ cryptic ” peptides or RNAs as biomarkersor readouts of therapeutic ef fi cacy 22,26 .”
InfluentialMa, J., Liu, L., Song, L., Liu, J., Yang, L., Chen, Q., Wu, J. Y., & Zhu, L. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06261-6 · Cited by 23
Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations
Pottier, C. P., Mateiu, L. M., Baker, M., DeJesus‐Hernandez, M., Vicente, C. T., Finch, N. A., Tian, S., van Blitterswijk, M., Murray, M. E., Ren, Y., et al. (2021) · Brain · doi:10.1093/brain/awab437 · Cited by 22
Self-citationTsioras, K., Smith, K. C., Edassery, S. L., Garjani, M., Li, Y., Williams, C., McKenna, E. D., Guo, W., Wilen, A. P., Hark, T. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113160 · Cited by 24
NOS1AP is a novel molecular target and critical factor in TDP-43 pathology
Cappelli, S., Spalloni, A., Feiguin, F. M., Visani, G., Šušnjar, U., Brown, A., Phatnani, H. P., Kwan, J. Y., Sareen, D., Broach, J. R., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac242 · Cited by 18
“sured in a direct fashion, inclusion of cryptic exons within Stathmin-2 (STMN2) and Unc-13 homolog A (UNC13A) transcripts has recently been proposed as representing a proxy of TDP-43 pathology.(37,38) Looking at NOS1AP levels across various brain regions of patients with reported TDP-43 pathology, in which we could ad…”
BackgroundMethodSelf-citationTDP-43 and NEAT long non-coding RNA: Roles in neurodegenerative disease
Sekar, D., Tusubira, D., & Ross, K. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.954912 · Cited by 21
“Beyond these studies, there is clearly an urgent need to establish whether TDP-43-binding oligonucleotides can restore the ability of TDP-43 to suppress splicing of the cryptic STMN2 and UNC13A exons implicated in neurodegeneration (Klim et al., 2019; Melamed et al., 2019; Prudencio et al., 2020; Brown et al., 2022; M…”
BackgroundTargeting Progranulin as an Immuno-Neurology Therapeutic Approach
Boylan, M. A., Pincetic, A., Romano, G. J., Tatton, N. A., Kenkare-Mitra, S., & Rosenthal, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115946 · Cited by 19
“Loss of nuclear TDP-43 may lead to dysfunction in RNA splicing, leaving neurons, and in particular their axons, susceptible [154].”
BackgroundXie, Y., Luo, X., He, H., & Tang, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657465 · Cited by 16
“The GSE153960 dataset includes 1,838 samples (non-neurological control, ALS spectrum motor neuron disease [MND], other neurological disorders, other MND, and familial ALS) and mRNA expression data derived from postmortem tissue specimens of the cerebellum, cortex, spinal cord, and hippocampus (Prudencio et al., 2020).”
BackgroundTDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration
Buciuc, M., Martin, P. R., Tosakulwong, N., Murray, M. E., Petrucelli, L., Senjem, M. L., Spychalla, A. J., Knopman, D. S., Boeve, B. F., Petersen, R. C., et al. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.102954 · Cited by 17
Self-citationGrima, N., Smith, A., Shepherd, C. E., Henden, L., Zaw, T., Carroll, L., Rowe, D. B., Kiernan, M. C., Blair, I. P., & Williams, K. L. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00820-5 · Cited by 17
“Previous examination of the STMN2 and UNC13A cryptic exons in bulk CNS RNA-seq found that they were largely detected in the motor cortex and spinal cord of ALS cases, and the frontal and temporal cortices of FTLD cases, the primary sites of pTDP-43 pathology [26, 27, 64].”
Reyes‐Leiva, D., Dols‐Icardo, O., Sirisi, S., Cortés‐Vicente, E., Turón‐Sans, J., de Luna, N., Blesa, R., Belbin, O., Montal, V., Alcolea, D. A., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.750543 · Cited by 19
“The expression of STMN2 is increased in the frontal cortex of patients with the TDP subtype of FTLD, which makes it a good candidate biomarker related to TDP pathology (204).”
BackgroundRNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy
Necarsulmer, J., Simon, J. M., Evangelista, B., Chen, Y., Tian, X., Nafees, S., Gonzalez, A. M., Jiang, H., Wang, P., Ajit, D., et al. (2023) · eLife · doi:10.7554/elife.85921 · Cited by 33
Koike, Y. M. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.05.001 · Cited by 17
“Moreover, truncated STMN2 mRNA levels correlate with phosphorylated TDP-43 protein levels and an earlier onset of FTD symptoms (Prudencio et al., 2020).”
BackgroundRothstein, J. D., Warlick, C., & Coyne, A. N. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.12.571299 · Cited by 20
Cheng, F., Chapman, T. R., Zhang, S., Morsch, M., Chung, R. S., Lee, A., & Rayner, S. L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102246 · Cited by 17
Keeley, O., & Coyne, A. N. (2024) · Nucleus · doi:10.1080/19491034.2024.2349085 · Cited by 16
“As a result, future studies are necessary to determine whether TDP-43 function is disrupted in models of CHMP2B FTD/ALS and whether this contributes to disease pathogenesis as has been recently observed in other forms of ALS/ FTD [63,64,70,76,254–256].”
Ko, Y., Lokareddy, R. K., Doll, S. G., Yeggoni, D. P., Girdhar, A., Mawn, I., Klim, J. R., Rizvi, N. F., Meyers, R. E., Gillilan, R. E., et al. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168751 · Cited by 18
Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis
Ito, D. (2021) · Annals of Neurology · doi:10.1002/ana.26259 · Cited by 16
“The loss of TDP-43 enables the incorporation of a premature poly A tail, resulting in a truncated and nonfunctional form of STMN2.”
BackgroundRochat, C., Bernard‐Marissal, N., Källstig, E., Pradervand, S., Perrin, F. E., Aebischer, P., Raoul, C., & Schneider, B. L. (2022) · Glia · doi:10.1002/glia.24140 · Cited by 15
Dilcher, R., Malpas, C. B., O'Brien, T. J., & Vivash, L. E. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221171 · Cited by 14
Microtubules, Membranes, and Movement: New Roles for Stathmin‐2 in Axon Integrity
Thornburg‐Suresh, E. J. C., & Summers, D. W. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25382 · Cited by 20
Dykstra, M. M., Weskamp, K., Gómez, N., Waksmacki, J., Tank, E. M. H., Glineburg, M. R., Snyder, A. G., Pinarbasi, E. S., Bekier, M. E., Li, X., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115113 · Cited by 23
“10, 13 To determine if sTDP43 is Based on these data, we next investigated whether sTDP43 accumulation causes toxicity and STMN2 missplicing in human neurons. iNeurons were transduced with lentiviral vectors expressing untagged sTDP43, and the cells were followed up for 10 days in culture through…”
Self-citationTDP‐43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP‐43 Proteinopathies
Pickles, S. R., Bejarano, J. G., Narayan, A., Daughrity, L. M., Cidfuentes, C. M., Reeves, M. M., Yue, M., Otero, P. C., Ayuso, V. E., Dunmore, J. H., et al. (2025) · Movement Disorders · doi:10.1002/mds.30104 · Cited by 15
“22,26,28,30 Further, they represent both neuronal ( ACTL6B , CAMK2B , STMN2 , UNC13A , and KCNQ2 ) and nonneuronal ( ATG4B , GPSM2 , and HDGFL2 ) targets (Fig.”
Self-citationThe role of endolysosomal progranulin and TMEM106B in neurodegenerative diseases
Takahashi, H., & Strittmatter, S. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00873-6 · Cited by 16
“…GRN homozygous null ( GRN −/− ) human mature brain organoids composed of iPSC-derived cortical neurons and astrocytes have been shown to recapitulate TDP-43 mis-localization, hyperphosphorylation, and mis-splicing of STMN2 transcripts [204], which is an indicator of TDP-43 pathology [205].”
Brown, A., Wilkins, O. G., Keuss, M. J., Kargbo-Hill, S. E., Zanovello, M., Lee, W. C., Lee, F. C. Y., Masino, L., Qi, Y. A., Bryce-Smith, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.02.438170 · Cited by 18
Self-citationNguyen, T. B., Miramontes, R., Chillon-Marinas, C., Maimon, R., Vazquez-Sanchez, S., Lau, A. L., McClure, N. R., England, W. E., Singha, M., Stocksdale, J. T., et al. (2023) · doi:10.1101/2023.10.31.565004 · Cited by 15
“TDP-43 acts as a repressor of cryptic exons (CE) in ALS/FTD with TDP-43 nuclear loss resulting in increased inclusion of CE 34–36 , 76 .”
BackgroundPeters, O. M., & Brown, R. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00026-5 · Cited by 12
Metadata
- Authors
- Prudencio, M., Humphrey, J., Pickles, S., Brown, A.-L., Hill, S. E., Kachergus, J. M., Shi, J., Heckman, M. G., Spiegel, M. R., Cook, C., Song, Y., Yue, M., Daughrity, L. M., Carlomagno, Y., Jansen-West, K., de Castro, C. F., DeTure, M., Koga, S., Wang, Y.-C., Sivakumar, P., Bodo, C., Candalija, A., Talbot, K., Selvaraj, B. T., Burr, K., Chandran, S., Newcombe, J., Lashley, T., Hubbard, I., Catalano, D., Kim, D., Propp, N., Fennessey, S., Fagegaltier, D., Phatnani, H., Secrier, M., Fisher, E. M. C., Oskarsson, B., van Blitterswijk, M., Rademakers, R., Graff-Radford, N. R., Boeve, B. F., Knopman, D. S., Petersen, R. C., Josephs, K. A., Thompson, E. A., Raj, T., Ward, M., Dickson, D. W., Gendron, T. F., Fratta, P., & Petrucelli, L.
- Affiliations
- Mayo Clinic (US)
- Icahn School of Medicine at Mount Sinai (US)
- UCL Queen Square Institute of Neurology (GB)
- University of Oxford (GB)
- UK Dementia Research Institute (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- New York Genome Center (US)
- University College London (GB)
- National Institutes of Health (US)
- Corresponding author
- Fratta, Pietro
- Petrucelli, Leonard
- ORCID
- Prudencio, Mercedes
- Humphrey, Jack
- Pickles, Sarah
- Brown, Anna-Leigh
- Hill, Sarah E.
- Shi, J.
- Heckman, Michael G.
- Spiegel, Matthew R.
- Cook, Casey
- Song, Yuping
- Daughrity, Lillian M.
- Carlomagno, Yari
- Jansen-West, Karen
- DeTure, Michael
- Koga, Shunsuke
- Wang, Ying-Chih
- Bodo, Cristian
- Candalija, Ana
- Talbot, Kevin
- Selvaraj, Bhuvaneish T.
- Chandran, Siddharthan
- Newcombe, Jia
- Lashley, Tammaryn
- Hubbard, Isabel
- Propp, Nadia
- Fennessey, Samantha
- Fagegaltier, Delphine
- Phatnani, Hemali
- Secrier, Maria
- Fisher, Elizabeth M.C.
- Oskarsson, Björn
- van Blitterswijk, Marka
- Rademakers, Rosa
- Boeve, Bradley F.
- Knopman, David S.
- Petersen, Ronald C.
- Josephs, Keith A.
- Thompson, E. Aubrey
- Raj, Towfique
- Ward, Michael
- Dickson, Dennis W.
- Gendron, Tania F.
- Fratta, Pietro
- Petrucelli, Leonard
- Venue
- Journal of Clinical Investigation
- Published
- 2020-10-19
- Volume
- 130
- Issue
- 11
- Pages
- 6080-6092
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7598060
- OpenAlex
- W3049616059
- Cited by
- 231
- References
- 68
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 54 · 2023: 48 · 2022: 30 · 2021: 19 · 2020: 2
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- NINDS and others, see below (see below)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- STMN2, TDP-43 pathology, frontotemporal dementia, FTLD-TDP, FTLD-tau, diagnostic biomarkers, iPSC-derived neurons, TARDBP mutations, phosphorylated TDP-43, age of disease onset, progressive supranuclear palsy, RNA expression
- MeSH terms
- DNA-Binding Proteins, Female, Frontal Lobe, Humans, Male, Middle Aged, Mutation, Biomarkers, Stathmin, Induced Pluripotent Stem Cells, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.